Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company.

A number of research analysts have recently commented on the stock. Zacks Research upgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a research note on Wednesday, May 6th. They issued a “buy” rating for the company. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday.

Swedish Orphan Biovitrum Price Performance

BIOVF opened at $48.00 on Friday. Swedish Orphan Biovitrum has a 12 month low of $27.06 and a 12 month high of $48.00. The company has a 50 day moving average of $47.06 and a 200 day moving average of $41.21. The company has a current ratio of 0.70, a quick ratio of 0.47 and a debt-to-equity ratio of 0.19. The company has a market cap of $17.09 billion, a PE ratio of 160.00 and a beta of 0.35.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.07. The company had revenue of $755.76 million during the quarter, compared to analysts’ expectations of $749.76 million. Swedish Orphan Biovitrum had a return on equity of 16.66% and a net margin of 3.37%. On average, sell-side analysts expect that Swedish Orphan Biovitrum will post 2.22 EPS for the current year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.